Original research
by
Enns, Benjamin et al
Release Date
2023
Geography
Canada
Language of Resource
English
Full Text Available
Yes
Open Access / OK to Reproduce
Yes
Peer Reviewed
Yes
Objective
Our objective was to examine the cost-effectiveness of flexible take-home buprenorphine-naloxone (BNX) versus methadone alongside the OPTIMA trial in Canada.
Findings/Key points
Flexible take-home BNX was not cost-effective versus methadone over a lifetime time horizon, resulting from better treatment retention in methadone compared to BNX.
Design/methods
The OPTIMA study was a pragmatic, open-label, noninferiority, two-arm randomized controlled trial, to assess the comparative effectiveness of flexible take-home BNX vs. methadone in routine clinical care for individuals with prescription-type opioid use disorder.
Keywords
Substitution/OAT
Outcomes
